Navigation Links
Pharmasset Appoints Herbert J. Conrad as a Director
Date:3/27/2008

nt of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: +1 (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that we cannot enroll enough patients for the Phase 3 registration clinical trial for clevudine, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to diff
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
11. Codexis Appoints Singapore Laboratories Managing Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Clintrax Global, Inc., ... in Raleigh, NC , recently ... as Vice President of Administration. ... all corporate processes, including their alignment with company ... Brad worked as an HR executive, specializing in ...
(Date:8/20/2014)... it that American Indians largely were wiped out by ... tuberculosis brought to the New World by European explorers., ... people lived in the Americas shortly before Europeans arrived, ... European diseases., But new research led by anthropological geneticists ... of the University of Tubingen in Germany indicates the ...
(Date:8/20/2014)... Fla. , Aug. 20, 2014 ... will host a conference call to provide an ... 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. ... 9126599 Live web cast: www.neurotropebioscience.com , under "Investor ... hours after completion through September 2, 2014 at ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group finds that the vascular ... Russia , India and ... 2013, roughly equal to the size of the United ... market will experience much faster growth as a result of strong ... Other key findings from Decision Resources Group,s coverage of the ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Neurotrope To Host Conference Call 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported ... that supports the broad anti-viral potential of the ... its PS-targeting drug bavituximab can cure lethal virus ... Bavituximab is in clinical trials for the treatment ...
... ILE ) today announced that on March ... "Exchange") notifying the Company it is not in compliance ... "Company Guide"). Specifically, the Exchange staff noted that the ... to its overall operations or its existing financial sources ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ... I/II U.K. trial of REOLYSIN(R) combined with paclitaxel/carboplatin for ... International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting ... to 22nd, 2009. The principal investigator for the trial ...
Cached Biology Technology:Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 2Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 3Isolagen, Inc. Receives Notification Letter from Amex 2Isolagen, Inc. Receives Notification Letter from Amex 3Isolagen, Inc. Receives Notification Letter from Amex 4Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial 3
(Date:8/21/2014)... team of researchers at Louisiana Tech University ... affordable, consumer-grade 3D printers and materials to ... antibacterial and chemotherapeutic compounds for targeted drug ... students and research faculty from Louisiana Tech,s ... to create filament extruders that can make ...
(Date:8/21/2014)... itself resulting in severe abdominal pain, vomiting and systemic ... are diagnosed with the disease resulting in 1000 deaths. ... to intravenous fluid and nutritional support. , Dr ... led the research, said "The major causes of pancreatitis ... alcohol intake combined with a high fat diet. In ...
(Date:8/20/2014)... CITY Researchers at Huntsman Cancer Institute (HCI) at the ... of the gene that encodes BCR-ABL, the unregulated enzyme ... to the American Cancer Society, nearly 6,000 new cases ... already in use, called tyrosine kinase inhibitors (TKIs), target ... do not cure CML but control it in a ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... symptom of physical pain or stress. But now a ... showing that tears have emotional benefits and can make ... Hasson of TAU,s Department of Zoology shows that tears ... an evolution-based mechanism to bring people closer together. ...
... by climate scientists at the University of East Anglia (UEA) ... field in the last two years. The article, ,Tipping ... Proceedings of the National Academy of Sciences in ... Paper, by Thomson Reuters. "The article captures the zeitgeist ...
... female cells counteract their double dose of X chromosomes by coating ... binds to the same X chromosome from which it is transcribed ... silencing. In the August 24, 2009 issue of the Journal ... the fact that XIST temporarily dissociates from the X chromosome during ...
Cached Biology News:Trust in a teardrop 2Tipping elements remain a 'hot' issue 2Tipping elements remain a 'hot' issue 3Aurora B answers an XIST-ential question 2
UBC13 Antibody...
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Phenytoin-BSA Isolated IgY DFc Drug...
Tropomyosin 4 [Tm4]...
Biology Products: